Literature DB >> 25491892

Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.

K Kumagai1, I Rouvelas2, J A Tsai2, D Mariosa3, P A Lind4, M Lindblad2, W Ye3, L Lundell2, C Schuhmacher5, M Mauer6, B H Burmeister7, J M Thomas7, M Stahl8, M Nilsson2.   

Abstract

Several phase I/II studies of chemoradiotherapy for gastric cancer have reported promising results, but the significance of preoperative radiotherapy in addition to chemotherapy has not been proven. In this study, a systematic literature search was performed to capture survival and postoperative morbidity and mortality data in randomised clinical studies comparing preoperative (chemo)radiotherapy or chemotherapy versus surgery alone, or preoperative chemoradiotherapy versus chemotherapy for gastric and/or gastro-oesophageal junction (GOJ) cancer. Hazard ratios (HRs) for overall mortality were extracted from the original studies, individual patient data provided from the principal investigators of eligible studies or the earlier published meta-analysis. The incidences of postoperative morbidities and mortalities were also analysed. In total 18 studies were eligible and data were available from 14 of these. The meta-analysis on overall survival yielded HRs of 0.75 (95% CI 0.65-0.86, P < 0.001) for preoperative (chemo)radiotherapy and 0.83 (95% CI 0.67-1.01, P = 0.065) for preoperative chemotherapy when compared to surgery alone. Direct comparison between preoperative chemoradiotherapy and chemotherapy resulted in an HR of 0.71 (95% CI 0.45-1.12, P = 0.146). Combination of direct and adjusted indirect comparisons yielded an HR of 0.86 (95% CI 0.69-1.07, P = 0.171). No statistically significant differences were seen in the risk for postoperative morbidity or mortality between preoperative treatments and surgery alone, or preoperative (chemo)radiotherapy and chemotherapy. Preoperative (chemo)radiotherapy for gastric and GOJ cancer showed significant survival benefit over surgery alone. In comparisons between preoperative chemotherapy and (chemo)radiotherapy, there is a trend towards improved survival when adding radiotherapy, without increased postoperative morbidity or mortality.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Gastro-oesophageal junction; Preoperative chemoradiotherapy; Preoperative chemotherapy; Stomach

Mesh:

Year:  2014        PMID: 25491892     DOI: 10.1016/j.ejso.2014.11.039

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  The value of esophagectomy surgical apgar score (eSAS) in predicting the risk of major morbidity after open esophagectomy.

Authors:  Xue-Zhong Xing; Hai-Jun Wang; Shi-Ning Qu; Chu-Lin Huang; Hao Zhang; Hao Wang; Quan-Hui Yang; Yong Gao
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Adjuvant radiochemotherapy in locally advanced gastric cancer : Treatment results and analysis of possible prognostic factors.

Authors:  Mercedes Martín Sánchez; Maria Ángeles Pérez Escutia; David Lora Pablos; Sandra Guardado Gonzales; Ana María Cabezas Mendoza; Arantxa Campos Bonel; Héctor Pérez Montero; Rafael D'Ambrosi; José Fermín Pérez-Regadera Gómez
Journal:  Strahlenther Onkol       Date:  2017-07-03       Impact factor: 3.621

Review 3.  Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives.

Authors:  Alberto Biondi; Maria C Lirosi; Domenico D'Ugo; Valeria Fico; Riccardo Ricci; Francesco Santullo; Antonia Rizzuto; Ferdinando Cm Cananzi; Roberto Persiani
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

4.  Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery : Long-term results.

Authors:  Stephanie Vitz; Holger Göbel; Bernhard Leibl; Thomas Aigner; Gerhard G Grabenbauer
Journal:  Strahlenther Onkol       Date:  2018-06-05       Impact factor: 3.621

5.  A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer.

Authors:  Kunning Wang; Enxiao Li; Rita A Busuttil; Joseph C Kong; Sharon Pattison; Joseph J Y Sung; Jun Yu; Emad M El-Omar; Julie A Simpson; Alex Boussioutas
Journal:  Ther Adv Med Oncol       Date:  2020-07-23       Impact factor: 8.168

6.  Updated experiences with minimally invasive McKeown esophagectomy for esophageal cancer.

Authors:  Ju-Wei Mu; Shu-Geng Gao; Qi Xue; You-Sheng Mao; Da-Li Wang; Jun Zhao; Yu-Shun Gao; Jin-Feng Huang; Jie He
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

7.  Consistency mapping of 16 lymph node stations in gastric cancer by CT-based vessel-guided delineation of 255 patients.

Authors:  Shuhang Xu; Lingling Feng; Yongming Chen; Ying Sun; Yao Lu; Shaomin Huang; Yang Fu; Rongqin Zheng; Yujing Zhang; Rong Zhang
Journal:  Oncotarget       Date:  2017-06-20

Review 8.  Progress of preoperative and postoperative radiotherapy in gastric cancer.

Authors:  Nan Zhang; Qian Fei; Jiajia Gu; Li Yin; Xia He
Journal:  World J Surg Oncol       Date:  2018-09-13       Impact factor: 2.754

9.  Outcomes of radiation therapy for resectable M0 gastric cancer.

Authors:  Weipeng Gong; Hongwei Zhao; Shanshan Liu; Jie Guan; Xin Liu; Qingsheng Hou; Zhenyu Zhu; Hongliang Guo
Journal:  Oncotarget       Date:  2017-11-03

10.  Calcification score versus arterial stenosis grading: comparison of two CT-based methods for risk assessment of anastomotic leakage after esophagectomy and gastric pull-up.

Authors:  De-Hua Chang; Sebastian Brinkmann; Lucy Smith; Ingrid Becker; Wolfgang Schroeder; Arnulf H Hoelscher; Stefan Haneder; David Maintz; Judith Eva Spiro
Journal:  Ther Clin Risk Manag       Date:  2018-04-17       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.